Your session is about to expire
← Back to Search
Antisense Oligonucleotide
BP1002 for Lymphoma
Phase 1
Recruiting
Research Sponsored by Bio-Path Holdings, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Females must be of non-childbearing potential, surgically sterile, postmenopausal, or practice adequate methods of contraception during the study
Eastern Cooperative Oncology Group (ECOG) Performance score of 0, 1, or 2
Must not have
Females who are pregnant, test positive for pregnancy, or are breast-feeding during the Screening period, or intend to become pregnant or breast-feed during the course of the study or within 30 days after last dose of study drug
Uncontrolled active, untreated, or progressive infection
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 210 days
Awards & highlights
Summary
This trial is testing a new drug for patients with advanced lymphoma who have relapsed or are resistant to treatment. Up to 12 patients will be given the drug and monitored for safety and effectiveness.
Who is the study for?
Adults over 18 with advanced lymphoid malignancies that have not responded to or returned after treatment, including various types of lymphoma and leukemia. Participants must be expected to live at least 3 months, have good liver and kidney function, and use contraception if applicable. They should not be eligible for certain other cancer treatments.
What is being tested?
The trial is testing BP1002 (L-Bcl-2 antisense oligonucleotide) for safety, how the body processes it, and its effectiveness in treating patients with relapsed or refractory lymphoid malignancies. Up to 12 patients will receive this experimental therapy.
What are the potential side effects?
Potential side effects are not explicitly listed but may include typical reactions associated with antisense oligonucleotides such as injection site reactions, flu-like symptoms, fatigue, fever, nausea and potential liver enzyme elevations.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I cannot become pregnant, am surgically sterile, postmenopausal, or use reliable birth control.
Select...
I can take care of myself and am up and about more than half of my waking hours.
Select...
My lymphoma came back or didn't fully respond to treatment.
Select...
I've tried or can't use standard treatments, including stem cell transplant and CAR T-cell therapy.
Select...
My liver and kidney tests are within normal ranges.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am not pregnant, breastfeeding, nor plan to become pregnant or breastfeed during the study.
Select...
I do not have any untreated or uncontrolled infections.
Select...
I am able and willing to follow study instructions and communicate with the research team.
Select...
I haven't received any cancer treatment in the last 14 days.
Select...
I am eligible for high dose chemotherapy and a stem cell transplant using my own cells.
Select...
I have not had a heart attack, stroke, or similar event in the last 6 months.
Select...
I have seizures that are not controlled by medication.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 210 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~210 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Determine half-life plasma pharmacokinetics (PK) of BP1002
Determine pharmacokinetics (PK) of BP1002
Determine plasma pharmacokinetics (PK) of BP1002 using elimination rate constant
+7 moreSecondary study objectives
Activity of BP1002 on Bcl-2 expression in tumor samples
Determine estimates for event-free survival (EFS)
Determine estimates for progression-free survival (PFS)
+3 moreOther study objectives
Exploratory objective to correlate treatment response with cytogenetic characteristics
Exploratory objective to correlate treatment response with molecular characteristics
Trial Design
1Treatment groups
Experimental Treatment
Group I: BP1002 monotherapyExperimental Treatment1 Intervention
L-Bcl-2 Antisense oligonucleotide (BP1002) is given in a sequential, dose escalation design. Starting dose is 20mg/m\^2.
Find a Location
Who is running the clinical trial?
Bio-Path Holdings, Inc.Lead Sponsor
5 Previous Clinical Trials
266 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am 18 years old or older.You have a current infection of hepatitis B, hepatitis C, or HIV.I cannot become pregnant, am surgically sterile, postmenopausal, or use reliable birth control.I can take care of myself and am up and about more than half of my waking hours.My lymphoma came back or didn't fully respond to treatment.I do not have any untreated or uncontrolled infections.You are expected to live for at least 3 more months.I do not need therapy in my spinal fluid for brain involvement of my cancer.I've tried or can't use standard treatments, including stem cell transplant and CAR T-cell therapy.I am not pregnant, breastfeeding, nor plan to become pregnant or breastfeed during the study.I have recovered from previous cancer treatments, except for hair loss.I haven't had treatment for cancer, except for non-melanoma skin cancer, in the last year.I agree to use birth control during the study.I am able and willing to follow study instructions and communicate with the research team.My liver and kidney tests are within normal ranges.I haven't received any cancer treatment in the last 14 days.I am eligible for high dose chemotherapy and a stem cell transplant using my own cells.I have a slow-growing type of non-Hodgkin lymphoma.I am at high risk for TLS due to a large tumor or high lymphocyte count.I have not had a heart attack, stroke, or similar event in the last 6 months.I have seizures that are not controlled by medication.I have a diagnosis of a specific type of lymphoma or leukemia.
Research Study Groups:
This trial has the following groups:- Group 1: BP1002 monotherapy
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger